Save information for later
Sign Up

Learn About Non-Alcoholic Fatty Liver Disease

What is the definition of Non-Alcoholic Fatty Liver Disease?

Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

What are the causes of Non-Alcoholic Fatty Liver Disease?

The specific causes of NAFLD are unclear. Genetic variations and environmental factors contribute to the development of this complex disorder.

What are the different types of Non-Alcoholic Fatty Liver Disease?

Common conditions include: Nonalcoholic Steatohepatitis (NASH)

How prevalent is Non-Alcoholic Fatty Liver Disease?

NAFLD is a very common disorder, occurring in about 25 percent of the global population. Its prevalence is increasing along with the rising prevalence of obesity in industrialized societies, and it is now the most common chronic liver disorder in Western countries, including the United States. NAFLD is more prevalent in individuals of Hispanic, Native American, or Asian ancestry than in individuals of European or African ancestry.

Is Non-Alcoholic Fatty Liver Disease an inherited disorder?

An increased risk of developing NAFLD can be passed through generations in families, but the inheritance pattern is unknown. Variations in several genes as well as lifestyle and environmental factors contribute to the risk of developing this complex disorder.

Who are the top Non-Alcoholic Fatty Liver Disease Local Doctors?
Pediatrics | Internal Medicine
Pediatrics | Internal Medicine
24 Newton St, 
Southborough, MA 
 0.3 mi

David Carlson is a Pediatrics specialist and an Internal Medicine provider in Southborough, Massachusetts. Dr. Carlson and is rated as an Experienced provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Cerebral Hypoxia, Hyperhidrosis, Tracheitis, Type 2 Diabetes (T2D), and Gamma Knife Radiosurgery.

Radiology | Interventional Radiology
Radiology | Interventional Radiology

Reliant Medical Group Inc

24 -28 Newton St, 
Southborough, MA 
 0.3 mi

Bryan Suchecki is a Radiologist and an Interventional Radiologist in Southborough, Massachusetts. Dr. Suchecki has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Pleurisy, Lung Cancer, Pleural Effusion, Bone Graft, and Vertebroplasty.

 
 
 
 
Learn about our expert tiers
Learn More
Gastroenterology
Gastroenterology

West Suburban Gi, PC

28 Newton St, 1st Flr, 
Southborough, MA 
 0.4 mi

Daniel Donahue is a Gastroenterologist in Southborough, Massachusetts. Dr. Donahue and is rated as an Experienced provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Irritable Bowel Syndrome (IBS), Swallowing Difficulty, Painful Swallowing, Endoscopy, and Colonoscopy.

What are the latest Non-Alcoholic Fatty Liver Disease Clinical Trials?
A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

Summary: This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in thi...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Summary: Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflamm...

Who are the sources who wrote this article ?

Published Date: November 01, 2016
Published By: National Institutes of Health